Form 4: Relmada Therapeutics CEO Buys Shares
Insider Transaction (Form 4)
Sergio Traversa, Chief Executive Officer and a Director of Relmada Therapeutics, Inc., purchased 200,000 shares of common stock on September 9, 2026.
Summary
- Open-market purchase: acquired 100,000 Common Stock at $4.18 ($418,000) on September 9, 2026; holds 1,400,000 after (Direct).
- Open-market purchase: acquired 100,000 Common Stock at $4.10 ($410,000) on September 10, 2026; holds 1,500,000 after (Direct).
Sentiment
Score: 8
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $828,000, committing personal capital to the stock.
Insider Transactions
Sergio Traversa — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-09 | Open-market purchase | Common Stock | 100,000 | $4 | $418.0K | 1,400,000 |
| 2026-09-10 | Open-market purchase | Common Stock | 100,000 | $4 | $410.0K | 1,500,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-09 | Open-market purchase (100,000 shares) |
| 2026-09-10 | Open-market purchase (100,000 shares) |
Keywords
insider transaction, Form 4, RLMD, RELMADA THERAPEUTICS, INC., bullish, Sergio Traversa
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.